The National Blood Authority (NBA) has finalised the new contracts for the ongoing supply of clotting factor treatment products in Australia.
Previous treatment product contracts will expire on 30 June 2014 and a tender process has been carried out to replace these contracts.
As a result, some people with haemophilia A and B will have different and, in some cases, increased treatment options from 1 July 2014.
For people with haemophilia A, two clotting factor products will be available:
- ADVATE supplied by Baxter
- Xyntha supplied by Pfizer
This will involve a change for people currently treated with Kogenate FS (Bayer).
For people with haemophilia B, two treatment products will now be available:
- BeneFIX supplied by Pfizer
- RIXUBIS supplied by Baxter and currently registered for treatment of adults.
HFA has been and will continue to be involved in discussions with the NBA and haemophilia health professionals about transition arrangements for people who will need to change products or where a new option is possible.
HFA recommends that people with haemophilia discuss their options with their doctor so that the most suitable product is used for their treatment.
For details of the tender outcomes please visit the NBA website where you will also find FAQs and information about transition arrangements.
The recent tender did not include longer acting clotting factors, such as Alprolix (Biogen Idec) which was approved for the treatment of haemophilia B in Australia this month. HFA will discuss with Australian Haemophilia Centre Director’s Organisation (AHCDO) and the NBA the processes for making this product available to Australians with haemophilia B and for any other longer acting products that are registered in the future.
These are important matters that affect your treatment. Please contact HFA if you have questions or concerns about them.
T: 1800 807 173